Patents by Inventor Miia LEHTINEN

Miia LEHTINEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for isolating human cardiac ventricular progenitor cells
    Patent number: 11401508
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 2, 2022
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Jonathan Clarke, Miia Lehtinen, Kylie Foo, Chuen Yan Leung
  • METHODS FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS
    Publication number: 20200140819
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Application
    Filed: October 29, 2019
    Publication date: May 7, 2020
    Inventors: Kenneth R. CHIEN, Jonathan CLARKE, Miia LEHTINEN, Kylie FOO, Chuen Yan LEUNG
  • Methods for isolating human cardiac ventricular progenitor cells
    Patent number: 10508263
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: December 17, 2019
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Jonathan Clarke, Miia Lehtinen, Kylie Foo, Chuen Yan Leung
  • METHODS FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS
    Publication number: 20180148691
    Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.
    Type: Application
    Filed: November 7, 2017
    Publication date: May 31, 2018
    Inventors: Kenneth R. CHIEN, Jonathan CLARKE, Miia LEHTINEN, Kylie FOO, Chuen Yan LEUNG